AstraZeneca PLC Publication of a Prospectus (0175C)
June 12 2019 - 11:45AM
UK Regulatory
TIDMAZN
RNS Number : 0175C
AstraZeneca PLC
12 June 2019
12 June 2019 16:45 BST
Publication of Prospectus
Following a routine technical update of the Company's Euro
Medium Term Note ("EMTN") programme established in 2007, the
following prospectus has been approved by the UK Listing Authority
and is available for viewing:
Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000
Euro Medium Term Note Programme (the "Prospectus").
The last drawdown under the EMTN programme was in 2016.
To view the full document, please paste the following URL into
the address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/0175C_1-2019-6-12.pdf
A copy of the above Prospectus has been submitted to the
National Storage Mechanism and will shortly be available for
inspection at:
http://www.morningstar.co.uk/uk/NSM
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please visit
astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharma +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma (cardiovascular; metabolism) +44 203 749 5711
Nick Stone BioPharma (respiratory; renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access, retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PDICKBDBPBKDQAD
(END) Dow Jones Newswires
June 12, 2019 11:45 ET (15:45 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
